Biogen Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for neurological and other serious diseases. Key marketed products include LEQEMBI (Alzheimer's disease), SKYCLARYS (Friedreich's ataxia), and TYSABRI. The company also develops biosimilars and has a pipeline including felzartamab, litifilimab, and salanersen, with collaborations with partners such as Eisai and Supernus.
expected 2026-07-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-06 | 2025-12-31 | 0000875045-26-000013 | EDGAR | 110K words |
| 2025-02-12 | 2024-12-31 | 0000875045-25-000009 | EDGAR | — |
| 2024-02-14 | 2023-12-31 | 0000875045-24-000009 | EDGAR | — |
| 2023-02-15 | 2022-12-31 | 0000875045-23-000009 | EDGAR | — |
| 2022-02-03 | 2021-12-31 | 0000875045-22-000007 | EDGAR | — |
| 2021-02-03 | 2020-12-31 | 0000875045-21-000010 | EDGAR | — |
| 2020-02-06 | 2019-12-31 | 0000875045-20-000005 | EDGAR | — |
| 2019-02-06 | 2018-12-31 | 0000875045-19-000006 | EDGAR | — |
| 2018-02-01 | 2017-12-31 | 0000875045-18-000005 | EDGAR | — |
| 2017-02-02 | 2016-12-31 | 0000875045-17-000009 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0000875045-25-000049 | EDGAR | 60K words |
| 2025-07-31 | 2025-06-30 | 0000875045-25-000033 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0000875045-25-000018 | EDGAR | — |
| 2024-10-30 | 2024-09-30 | 0000875045-24-000032 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000875045-24-000025 | EDGAR | — |
| 2024-04-24 | 2024-03-31 | 0000875045-24-000016 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0000875045-23-000038 | EDGAR | — |
| 2023-07-25 | 2023-06-30 | 0000875045-23-000030 | EDGAR | — |
| 2023-04-25 | 2023-03-31 | 0000875045-23-000016 | EDGAR | — |
| 2022-10-25 | 2022-09-30 | 0000875045-22-000031 | EDGAR | — |
| 2022-07-20 | 2022-06-30 | 0000875045-22-000025 | EDGAR | — |
| 2022-05-03 | 2022-03-31 | 0000875045-22-000016 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-04-06 | 0000875045-26-000039 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-134889 | EDGAR | — |
| 2026-03-11 | 0000950157-26-000280 | EDGAR | — |
| 2026-02-11 | 0001193125-26-046803 | EDGAR | — |
| 2026-02-06 | 0000875045-26-000011 | EDGAR | — |
| 2026-01-14 | 0000875045-26-000003 | EDGAR | — |
| 2025-10-30 | 0000875045-25-000047 | EDGAR | — |
| 2025-10-14 | 0000875045-25-000040 | EDGAR | — |
| 2025-07-31 | 0000875045-25-000035 | EDGAR | — |
| 2025-07-07 | 0000875045-25-000027 | EDGAR | — |
179 total filings indexed. 147 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000875045 |
| Ticker | BIIB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.biogen.com |
| Listed | 1991-09-17 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report